What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer
- PMID: 28149904
- PMCID: PMC5233500
- DOI: 10.21037/atm.2016.11.77
What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer
Conflict of interest statement
The authors have no conflicts of interest to declare.
Comment on
-
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021. Sci Transl Med. 2015. PMID: 26311728
References
-
- Harris LN, Ismaila N, McShane LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34:1134-50. 10.1200/JCO.2015.65.2289 - DOI - PMC - PubMed
-
- Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer Version 2.2015. J Natl Compr Canc Netw 2015;13:448-75. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources